LUPIN LTD

A comparitive report of pharmaceuticalcompanies Click to edit Master subtitle style

5/22/12

PHARMACEUTICAL INDUSTRY

The pharmaceutical industry develops, produces, and markets drugs licensed for use as medications. Pharmaceutical companies are allowed to deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs.

5/22/12

 As

for many other major industries since the middle of the twentieth century, the pharmaceutical industry has been portrayed as a global shadowy force in numerous western fiction works. Notorious films such as The Fugitive (1993) and Resident evil and novels/films such as The Constant Gardener characterize this trend.

5/22/12

PHARMACEUTICAL INDUSTRY IN INDIA

The

Pharmaceutical industry in India is the world's third-largest in terms of volume and stands 14th in terms of value. According to Department Pharmaceuticals, Ministry of Chemicals and Fertilizers the total turnover of India's pharmaceuticals industry between 2008 and September 2009 was US$21.04 billion. While the domestic market was worth US$12.26 billion

5/22/12

Sale of all types of medicines in the country is expected to reach around US$19.22 billion by 2012. Exports of pharmaceuticals products from India increased from US$6.23 billion in 2006-07 to US$8.7 billion in 2008-09 a combined annual growth rate of 21.25%. to PricewaterhouseCoopers (PWC) in 2010, India joined among the league of top 10 global pharmaceuticals markets in terms of sales by 2020 with value reaching US$50 billion.
5/22/12

According

TOP TEN PHARMACEUTICAL COMPANIES IN INDIA

RANK NAME OF THE REVENUE (USD COMPANY MILLION) 1 CIPLA 1348.51 2 RANBAXY 1327.56 3 DR REDDYS 1178.4 LABORATORIES 4 LUPIN LTD 929.84 5 AUROBINDO PHARMA865.19 6 7 DABUR 700.3 SUN 673.9 PHARMACEUTICALS

5/22/12

LUPIN LTD
Lupin

Ltd is world's largest manufacturer of the antiTB drugs. is based in Mumbai, India.

It It

is also India' fifth largest drug maker by revenue

5/22/12

The company production contains the Cardiovascular , Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy and world largest manufacturer of Anti-TB and Cephalosporins segments. is the first Asian country where the company has launched the new prescription drug after launching first anti TB drugs in single tablet. was founded by Desh Bandhu Gupta in 1968.

India

It

5/22/12

RECENT MIILESTONES
2011 Lupin Acquires Irom Pharmaceuticals through its Japanese Subsidiary. Lupin and Medicis Enter into Joint Development Agreement. Lupin acquires Worldwide Rights for the Goanna Brand. 2009 Lupin acquired majority stake in Multicare Pharmaceuticals Philippines Inc.

2008

5/22/12

MANAGEMENT OF THE COMPANY

q Dr

Desh Bandhu Gupta Chairman q Dr Kamal K

5/22/12

COMPARSION OF RESULTS OF COMPANIES

LUPIN REVENUE NET PROFIT EPS CASH EPS OPM % NPM % 1405.38 214.61 4.81 5.54 21.50 15.27 RANBAXY CIPLA 3887.72 1758 -2710.32 269.91 -64.28 -61.11 -59.39 -69.71 3.37 4.31 19.85 15.35 SUN PHARMA 1011.85 365.23 3.50 3.72 34.95 36.10
5/22/12

3years balance sheet of lupin Financial Expenses Depreciation Other Write offs Adjusted PBT Tax Charges Adjusted PAT Non Recurring Items Other Non Cash adjustments Reported Net Profit Earnigs Before Appropriation 1,686.27 1,848.19 1,146.19 1,083.18 0.00 0.00 8,665.70 6,305.81 2,912.44 2,168.50 5,753.26 4,137.31 1,107.89 909.49 0.00 0.00 1,489.50 973.40 0.00 7,018.90 2,114.87 4,904.03 297.71 0.00

6,865.69 5,046.80 5,201.74 19,633.8 14,555.7 11,589.20 5/22/12 0 8

Continuation of balance sheet

Uses of funds Fixed Assets Gross Block Less : Revaluation Reserve Less : Accumulated Depreciation Net Block Capital Work-in-progress Investments Net Current Assets Current Assets, Loans & Advances Less : Current Liabilities & 0.00 0.00 0.00 355.75 975.62 1,884.34 1,616.52 1,331.37 529.71 425.13 1,354.63 1,191.39

482.90 140.83 116.31 680.88 724.07 473.87 2,717.34 2,333.50 1,820.38

5/22/12 1,099.80 952.43 1,065.97

3years income statement of lupin

Income : Operating Income Expenses Material Consumed Manufacturing Expenses Personnel Expenses Selling Expenses Adminstrative Expenses Expenses Capitalised Mar ' Mar ' Mar ' 11 10 09 4,487.3 3,690.0 2,954.7 6 9 0 1,920.6 1,598.7 1,326.1 7 5 6 296.18 256.83 226.56 491.23 376.55 334.47 416.74 358.97 294.17 371.57 257.88 199.22 0.00 0.00 0.00 5/22/12 3,496.3 2,848.9 2,380.5

Continuation of income statement Financial Expenses 51.49 36.76

Depreciation Other Write offs Adjusted PBT Tax Charges Adjusted PAT Non Recurring Items Other Non Cash adjustments Reported Net Profit 104.28 0.00 81.57 0.00 59.73 -27.85 -1.08

49.99 66.35 0.00

838.16 35.65 802.51 7.36 0.11

736.51 461.52 54.41

676.78 407.11 9.45 0.40

809.98

648.93 416.97 5/22/12

STOCK MOVEMENT OF COMAPNIES

LUPI N

RANBAX Y

5/22/12

CIPLA

SUN PHARMA
5/22/12

CONCLUSION

My recommendation would be to buy lupin as its prices are low at the time being they are expected to rise in the next month. It would be a good option to hold it long term.

5/22/12